By Nikhil Sharma (Reuters) -European shares dipped on Wednesday, as the rise in healthcare companies after Novo Nordisk's ...

As per provisional closing, the S&P BSE Sensex, tumbled 312.53 points or 0.40% to 78,271.28. The Nifty 50 index fell 42.95 points or 0.18% to 23,696.30.

Despite trade tensions, US markets rebounded on Tuesday, recovering from steep losses on Monday. The S&P 500 climbed 0.7%, the NASDAQ Composite jumped 1.4%, and the Dow Jones Industrial Average edged ...

With the respite in U.S. tariffs on key countries, investors could turn their attention to earnings. But Alphabet earnings ...

Novo’s Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition ...

J&J, AstraZeneca, Novo Nordisk and Roche are among the companies that might take a hit from the soon-to-be-enacted fees, ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

The Novo Nordisk Foundation does not plan to step in to prop up a global health sector reeling from a freeze on U.S.-funded ...

President Donald Trump said his administration will install 25% tariffs on goods from Canada and Mexico, ending the largely ...

The pan-European STOXX 600 index was up 0.3%, as of 0810 GMT, after the benchmark closed at a record peak on Thursday following the European Central Bank's interest rate cut and dovish outlook.

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Jim Cramer in a latest program on CNBC reminded viewers about the Trump playbook in the story market and said that he never ...